24 results about "Lethal dose" patented technology

The invention belongs to the technical field of biology, and particularly relates to application of hepcidin expression quantity in larimichthys crocea liver as larimichthys crocea visceral white-spot disease resistance evaluation index and a construction method. The hepcidin expression quantity in the larimichthys crocea liver is applied as the larimichthys crocea visceral white-spot disease resistance evaluation index. The construction method of the resistance evaluation index comprises the following steps: taking healthy small yellow croaker intraperitoneal injection pseudomonas proteinus strain bacterial liquid, and determining a half lethal dose in 96 hours; the method comprises the following steps: injecting a half lethal dose of bacterial liquid of pseudomonas proteinus strains into the abdominal cavity of healthy small yellow croaker for 96 hours, and after infection, taking different tissues to carry out hepcidin gene expression fluorescent quantitative PCR analysis; a regression model of gene expression quantity and bacterium loading quantity is established through fluorescence quantification, and the relationship between hepcidin expression quantity and disease resistance is constructed. Accurate disease-resistant phenotype information is provided for development of breeding of visceral white-spot disease-resistant improved varieties of the small yellow croakers, the accuracy of disease-resistant breeding is promoted, early detection of diseases is realized, and prevention and treatment of the diseases are effectively guided.

The present invention relates to the technical field of crop breeding, and specifically discloses a composition for Co-60γ ray irradiation mutagenesis breeding of Dendrocalamus brandisii, which is composed of an irradiation pretreatment solution and an irradiation post-treatment solution. The present invention also provides a method for breeding Dendrocalamus brandisii by Co-60γ ray irradiation mutagenesis, which includes soaking the seeds of Dendrocalamus brandisii in an irradiation pretreatment solution containing L-hydroxyproline to fully imbibe them, irradiating them with Co-60γ rays at a semi-lethal dose, and then treating them with an irradiation post-treatment solution containing 2-hydroxyglutaric acid, glutathione and vitamin C. The method of the present invention effectively improves the mutagenesis efficiency of Dendrocalamus brandisii by adding L-hydroxyproline as an inducer for specific pretreatment before irradiation, adding 2-HG as an irradiation sensitizer, and adding GSH and Vc as radiation protectors for post-treatment after irradiation. Mutant plants with excellent traits are screened and can be used as new germplasms or new varieties of bamboo.

This invention belongs to the field of radiation mutagenesis technology, and relates to a method for mutagenesis of lavender seeds, employing... 60 Lavender seeds are treated with Co-γ rays; the radiation dose is 50-500 Gy, and the dose rate is 1-3 Gy / min. This invention employs... 60 Radiation with Co-γ rays can efficiently induce mutations in the genetic material of lavender seeds, effectively breaking gene linkage and significantly increasing the mutation frequency. This provides a rich material basis for screening lavender mutants, allowing for the selection of seed half-lethal doses, and obtaining plants with variations in leaf color, leaf shape, plant height, and other traits. This provides technical support for lavender breeding using radiation mutagenesis technology.

The invention relates to the technical field of drug side reaction risk prediction, in particular to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises a data acquisition module used for integrating multi-source time series data, including medication dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; the cumulative effect analysis module is used for calculating a drug attenuation factor, a binding dose and median lethal dose quantitative cumulative effect intensity based on first-order elimination kinetics, and capturing drug metabolic dynamics; due to the fact that the interaction influence effect possibly exists between the drugs, the influence coefficient analysis module is used for adopting elastic network regression and analyzing the drug main effect and the drug combination interaction effect, and determining the main influence coefficient and the interaction influence coefficient of the drugs on each clinical index; and the risk prediction module is used for weighting and optimizing decision tree sorting through the abnormal contribution degree, and outputting the risk probability of each side reaction in combination with a random forest algorithm.

The present invention provides an antibody that binds to the SFTSV glycoprotein Gn, and the antibody has a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region is as shown in any one of SEQ ID No.1, 3, 5, 7, 9, 11, 13; the amino acid sequence of the light chain variable region is as shown in any one of SEQ ID No.2, 4, 6, 8, 10, 12, 14. The antibody of the present invention has very high in vitro neutralization activity (IC 50 can be as low as 3.1 ng / mL), and the in vivo detection results show that it can effectively prevent mice from being infected with SFTSV. In the therapeutic experiment, a single-dose treatment was received 5 days after infection with a lethal dose, and the survival efficiency could also reach 80%; the antibody of the present invention can effectively treat mice infected with SFTSV and prevent SFTSV from infecting mice, and has extremely high application value for clinical treatment and prevention of SFTSV infection.

The invention provides a schizothorax fish fertilized egg ultraviolet radiation damage experiment device and method. The device comprises a life support system, a main experiment system, a water inlet and outlet system and an oxygen supply system. The top of the main experimental system is divided into four independent areas, a metal net bag is hung in each area through a fixing device, stable water flow is formed at the 45-degree inclination angle of the tail end of a water inlet pipe, and the life support system maintains the water temperature to be 13-18 DEG C and the water quality to be stable. The method comprises the following steps: acquiring ultraviolet data in a natural reproduction period, setting intensity (low / medium / high) and time (short / medium / long) gradients, irradiating fertilized eggs from P1 to P7 periods, counting a death rate and analyzing a semi-lethal dose. Water environment interference is eliminated through integrated design, an accurate and efficient ultraviolet radiation injury experiment is achieved, and the device is suitable for schizothorax fish fertilized egg protection research. Water environment interference is eliminated through integrated design, an accurate and efficient ultraviolet radiation injury experiment is achieved, and the device is suitable for schizothorax fish fertilized egg protection research.

The invention discloses a nano antibody T92-6 of an anti-tetanus toxin Hc structural domain and application of the nano antibody T92-6, and belongs to the field of immunotherapy biotechnology pharmacy. The nano antibody or the antigen binding fragment thereof comprises three complementarity determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is SEQ ID NO: 6, the amino acid sequence of the CDR2 is SEQ ID NO: 7, the amino acid sequence of the CDR3 is SEQ ID NO: 8, and the sequences of the complementarity determining regions are defined according to an IMGT numbering system. The antibody is only combined with THc protein, and poisoning caused by a lethal dose of tetanus toxin (10 * LD50) can be effectively blocked by 5 micrograms of the antibody; after being humanized, the antibody still has better affinity and neutralizing activity, and the antibody with the same dose can still effectively block poisoning caused by tetanus toxin (10 * LD50) with a lethal dose.

The present application relates to the technical field of drug side reaction risk prediction, and particularly relates to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises: a data acquisition module for integrating multi-source time series data, including drug dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; a cumulative effect analysis module for calculating a drug attenuation factor based on first-order elimination kinetics, quantifying the cumulative effect intensity in combination with the dosage and median lethal dose, and capturing the drug metabolism dynamics; since there may be interactive effects between drugs, an influence coefficient analysis module is used to analyze the drug main effect and the joint drug interaction effect by using elastic network regression, and to determine the main influence coefficient and the interaction influence coefficient of the drug on each clinical index; a risk prediction module for optimizing the decision tree sorting by the abnormal contribution degree weighting, and outputting the risk probability of each side reaction in combination with the random forest algorithm.

The present invention provides a precision radiotherapy system based on a four-dimensional adaptive digital tracking conformal intensity modulated focusing medical electron accelerator, comprising a radiotherapy planning system, a radiotherapy delivery system, a digital tracking system, a four-dimensional six-axis collaborative treatment bed, a three-dimensional four-axis dual digital X-ray fluoroscopy system, an integrated control system, and an auxiliary treatment system. The various systems are interconnected, and the three-dimensional four-axis dual digital X-ray fluoroscopy system and the tracker simultaneously collect data to establish a digital tracking model for tracking targets. The radiotherapy delivery system, in coordination with the radiotherapy planning system, the digital tracking model for tracking targets, the tracker, the four-dimensional six-axis collaborative treatment bed, the integrated control system, and the auxiliary treatment system, performs four-dimensional adaptive digital tracking conformal intensity modulated focusing irradiation on the target. The precision radiotherapy system has accurate radiotherapy planning, accurate radiotherapy delivery conformal shape, accurate radiotherapy delivery focusing, accurate radiotherapy delivery target tracking, accurate target dose, uniform target dose distribution, and a cliff-like drop in dose outside the target boundary. The system can deliver a lethal dose to the target at one time and provide personalized protection for tissues and organs outside the target from radiation damage.

The invention discloses a nano antibody TL-25 of an anti-tetanus toxin L-HN fragment and application of the nano antibody TL-25, and belongs to the field of immunotherapy biotechnology pharmacy. The nano antibody or the antigen binding fragment thereof comprises three complementarity determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is SEQ ID NO: 6, the amino acid sequence of the CDR2 is SEQ ID NO: 7, the amino acid sequence of the CDR3 is SEQ ID NO: 8, and the sequences of the complementarity determining regions are defined according to an IMGT numbering system. The antibody is only combined with TL-HN protein, and 0.3125 [mu] g of the antibody can effectively block poisoning caused by tetanus toxin (10 * LD50) in a lethal dose; after being humanized, the antibody still has better affinity and neutralizing activity, and the antibody with the same dose can still effectively block poisoning caused by tetanus toxin (10 * LD50) with a lethal dose.

The invention discloses a method for creating a rhododendron pulchrum mutant aseptic seedling by combining EMS mutagenesis and tissue culture. The method specifically comprises the following steps: (1) determination of EMS semi-lethal dose: preparing EMS solutions with different concentrations, and soaking rhododendron pulchrum seeds in the EMS solutions for mutagenesis to obtain soaked seeds; the soaked seeds are treated, the EMS solution left on the surfaces is removed, and mutagenesis seeds are obtained; placing the mutagenic seeds on wet filter paper in a container, and carrying out dark culture and germination acceleration; the germination rate and the germination potential are counted, and the EMS semi-lethal dose concentration is obtained; and (2) early screening of the rhododendron pulchrum mutant strain: carrying out seed soaking treatment by using the EMS solution with the semi-lethal dose concentration, and screening according to the phenotypic growth index of the rhododendron pulchrum seedling to obtain the rhododendron pulchrum mutant strain. According to the application, the genetic diversity of the rhododendron pulchrum is enriched, the existing development difficulty of the rhododendron pulchrum is broken through, and the wide application of the rhododendron pulchrum in landscape architecture is realized.

The invention discloses a calcium ion binding protein marker combination for evaluating individual radiosensitivity and application of the calcium ion binding protein marker combination, and belongs to the technical field of biotechnology and nuclear radiation protection. Aiming at the technical problems that a genomics detection method and a functional experiment method for evaluating individual radiosensitivity have obvious limitation and the like at present, the invention is based on a C57BL / 6J mouse half lethal dose radiation experiment for the first time; a radiosensitivity prediction model based on the serum calcium ion binding protein combination (Ihh, NUCB1 and PROS1) is screened and established through a high-throughput mass spectrometry technology, and the clinical application value of the serum calcium ion binding protein combination (Ihh, NUCB1 and PROS1) as the radiosensitivity prediction marker is proved for the first time. A novel molecular marker is provided for professional radiation protection monitoring and formulation of a precise tumor radiotherapy scheme.

The invention discloses a pharmaceutical composition for preventing and treating acute radiation sickness and application thereof. Animal experiments prove that the combined use of the estrogen anti-release drug and the thrombopoiesis promoting drug can obviously improve the survival rate of animals irradiated by lethal and even super lethal dose, can obviously increase the proportion and absolute quantity of hematopoietic stem cells and progenitor cells in bone marrow of the irradiated animals, and enhances the extramedullary hematopoietic activity of the spleen at the same time; and the recovery of hematopoietic functions of leukocytes, platelets and erythrocytes is promoted. According to the invention, the treatment effect on acute radiation sickness is remarkably improved by combining the estrogen drugs and the thrombopoiesis promoting drugs, and a new treatment scheme is provided for prevention and treatment of acute radiation sickness.

The invention discloses an anti-tetanus toxin bispecific neutralizing antibody as well as a related biological material and application thereof, and belongs to the field of immunotherapy biotechnology pharmacy. The bispecific antibody or the antigen binding fragment of the bispecific antibody comprises two humanized nano antibodies, namely T92-6-h2 and TL-25-h1, and amino acid sequences of three complementary determining regions CDR1, CDR2 and CDR3 of the T92-6-h2 are SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 in sequence; the amino acid sequences of three complementary determining regions CDR1, CDR2 and CDR3 of the TL-25-h1 are SEQ ID NO: 14, ID NO: 15 and SEQ ID NO: 16 in sequence; the sequence of the complementarity determining region is defined according to an IMGT numbering system. The antibody can be combined with an L-HN functional fragment and an Hc structural domain at the same time, and can effectively block poisoning caused by lethal dose tetanus toxin.

This application relates to the field of biotechnology, specifically to a highly UV-resistant Beauveria bassiana strain, its target mutagenesis method and uses. The highly UV-resistant Beauveria bassiana strain of this application has a preservation number of CGMCC No. 22466 and a preservation date of July 5, 2021. The strain is obtained by using the Beauveria bassiana wild strain CGMCC No. 13566 as the starting strain, through multiple repeated stresses by sub-lethal dose radiation simulating solar UVB and target selection, and has the property of high UV resistance. The fungal insecticide prepared by the strain can be successfully used all-weather in the green control of pests.

The application discloses a nanobody B12 and related biomaterials and applications thereof, and belongs to the field of immunotherapy biotechnology and pharmaceuticals, and particularly relates to the nanobody B12 and related biomaterials and applications thereof. The nanobody or antigen-binding fragment containing the nanobody targeting botulinum toxin type B has three complementarity determining regions CDR1, CDR2 and CDR3; the amino acid sequence of CDR1 is SEQ ID No. 1, the amino acid sequence of CDR2 is SEQ ID No. 2, and the amino acid sequence of CDR3 is SEQ ID No. 3. The nanobody B12 is fused with the Fc segment (hFc) of human immunoglobulin to obtain a fusion protein, and the obtained B12-hFc can effectively block the infection of botulinum toxin type B, and can resist 20LD 50 The half lethal dose ED of botulinum toxin is 0.28 μg. 50 ​

The invention discloses application of combination of dimethyl sulfoxide and thrombopoiesis promoting drugs in treatment of acute radiation sickness. It is found for the first time that a combined scheme of DMSO and thrombopoiesis promoting drugs can significantly improve the survival rate of animals irradiated by lethal and even super lethal dose, animal weight reduction caused by radiation is reversed, and a significant synergistic effect is shown. The invention provides a safe and reliable radiation prevention and treatment measure for patients suffering from acute high-dose radiation exposure, and has a wide clinical application scene.

The application discloses a nanobody against tetanus toxin L-HN fragment and related biomaterials and application thereof, and belongs to the field of immunotherapy biotechnology and pharmaceuticals. The aforementioned nanobody or antigen-binding fragment thereof comprises three complementarity determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is SEQ ID NO: 6, the amino acid sequence of the CDR2 is SEQ ID NO: 7, and the amino acid sequence of the CDR3 is SEQ ID NO: 8, and the sequence of the complementarity determining region is defined according to the IMGT numbering system. The antibody only binds to TL-HN protein, and 0.3125 μg of the antibody can effectively block poisoning caused by a lethal dose of tetanus toxin (10*LD 50 ); after humanization, the antibody still has good affinity and neutralization activity, and an equivalent dose of the aforementioned antibody can still effectively block poisoning caused by a lethal dose of tetanus toxin (10*LD 50 ).

The invention discloses an apolipoprotein marker combination for evaluating individual radiosensitivity and application thereof, and belongs to the technical field of biotechnology and nuclear radiation protection. Aiming at the technical problems that a genomics detection method and a functional experiment method for evaluating individual radiosensitivity have obvious limitations and the like at present, the invention screens and establishes a radiosensitivity prediction model based on serum apolipoprotein combinations (APOA1, APOA2 and APOA4) through a high-throughput mass spectrometry technology on the basis of a C57BL / 6J mouse half lethal dose radiation experiment for the first time; the clinical application value of the apolipoprotein combinations (APOA1, APOA2 and APOA4) as the radiosensitivity prediction marker is confirmed for the first time, and a novel molecular marker is provided for professional radiation protection monitoring and formulation of a precise tumor radiotherapy scheme.

This invention discloses the application of a pyrazole compound in the control of plant root-knot nematodes. This invention is the first to discover... N -(4,4-difluorocyclohexyl)-2-(3-methyl- 1H (-pyrazol-1-yl)-6-morpholinopyrimidine-4-amine exhibits strong toxic activity against various plant root-knot nematodes. Its 24-hour median lethal dose (LC50) is [not specified in the original text]. 50 The concentrations were 12.70 μg / ml, 24.35 μg / ml, and 20.57 μg / ml, respectively; the median lethal dose (LC50) at 48 hours was [not specified in the original text]. 50 The concentrations were 12.50 μg / ml, 23.46 μg / ml and 19.47 μg / ml, respectively, and the drug showed no toxic activity against non-plant pathogenic nematodes such as Caenorhabditis elegans. It is safe and efficient, providing new ideas and approaches for the development of new root-knot nematode insecticides.

The invention discloses an application of combination of an estrogen drug and DMSO in preparation of a drug for resisting radiation damage. It is found for the first time that combined administration of estrogen drugs and DMSO can significantly improve the survival rate of animals irradiated by a lethal dose and reverse animal weight loss caused by radiation, and a significant synergistic effect is shown; meanwhile, the ratio and the absolute quantity of hematopoietic stem cells and progenitor cells in bone marrow can be remarkably increased through combined medication of the hematopoietic stem cells and the progenitor cells, the extramedullary hematopoietic activity of the spleen is enhanced, and recovery of hematopoietic functions of leukocytes, platelets and The invention provides a new thought and direction for the field of radiation damage.

This invention discloses the application of hemp seed oil in the preparation of drugs for the prevention or mitigation of acute ionizing radiation-induced diseases, relating to the field of biomedical technology. This invention discovers that hemp seed oil can protect the intestinal epithelium and crypt structures under acute high-dose irradiation, maintaining the intestinal barrier and digestive function. Simultaneously, it can protect splenic immune function by slowing the reduction in the white pulp region of the spleen and increasing the number of nucleated cells and lymphoid immune cells in the spleen, thereby significantly improving the individual survival rate after lethal doses of radiation, providing a new approach for treating acute ionizing radiation-induced diseases.

The invention discloses a streptococcus suis self-assembled protein nanoparticle vaccine and application thereof, and belongs to the field of biological medicine. The preparation method comprises the following steps: constructing fusion protein nano-particles by using two antigen proteins, namely Antigen1 and Antigen2 of streptococcus suis through an I53-50 nano-particle skeleton, and mixing the two nano-particles to prepare the novel streptococcus suis nano-particle vaccine. Compared with an existing subunit vaccine, the protein nanoparticle vaccine can stimulate better humoral immunity and cellular immunity, and can provide better immune protection for lethal dose infection of streptococcus suis type 2 and streptococcus suis type 9. The swine streptococcosis nanoparticle vaccine does not need additional adjuvants, has the characteristics of simplicity in preparation, low cost and the like, and has a good application prospect in the development of swine streptococcosis vaccines.

The present invention discloses the use of N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-2,6-difluorobenzamide in preventing and controlling plant root-knot nematodes. The present invention is the first to discover that N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-2,6-difluorobenzamide has a strong toxic effect on a variety of plant root-knot nematodes, with a median lethal dose (LC50) of 100% for southern root-knot nematodes, javanic root-knot nematodes, and elephant ear bean root-knot nematodes within 24 hours. 50 The concentrations were 4.27 μg / ml, 8.38 μg / ml and 7.51 μg / ml respectively; the median lethal dose LC of the southern root-knot nematode, the javanic root-knot nematode and the elephant-ear root-knot nematode was 48 hours. 50 The concentrations are 4.11 μg / ml, 9.56 g / ml and 6.92 μg / ml respectively. It has no toxic activity against non-plant pathogenic nematodes such as Caenorhabditis elegans, has the characteristics of high efficiency and low toxicity, and can be used in the development and research of root-knot nematode insecticides.